Answers are grounded in this paper and cite their sources.
The current pharmacopoeiol limit tests for particulate contamination in parenteral solutions are critically reviewed and likely sources of contamination ore then discussed in relation to the manufacturing processes and subsequent handling of the products. The site at which a particle may be lodged within the body and the possible reaction to the particle is described following recent reports in the literature which make a connection between the particle dimensions and host response. In addition, attention is drawn to the effects which may be due to the chemical identity of the contamination, suggesting that cellulose, asbestos and talcum require to be totally excluded from intravenous products. inadequacies in the present limit tests are emphasized, and direction, for possible improvements are suggested.
No takes yet. Share an insight, caveat, or question.
Grovas et al. (1976) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: